|Other names||BAY 86-5310; SH-T04211C|
|Drug class||Estrogen; Selective ERβ agonist|
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms. It reached phase II clinical trials prior to the discontinuation of its development. Its development was terminated in 2014.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|